A team of CNIO researchers, in collaboration with the Spanish Oncology Genitourinary Group (SOGUG) and the University Hospitals Leuven (Belgium), has come across various potential predictive biomarkers of tyrosine kinase inhibitors (TKIs) response in metastatic renal cancer.

In their study, published in JCI Insight, the researchers identify various miRNAs that define a group of patients with the poorest response to TKI treatment -a type of anti-angiogenic agent widely used to treat renal cancer- and with the worst prognosis.

The study, conducted on 139 patient samples, is the most robust to date in renal cell carcinoma.

Finding biomarkers that can help determine a patient's prognosis, the risk of recurrence or, as in this case, their sensitivity to various treatments will improve personalised treatment for these patients.

Although there are dozens of predictive biomarkers for drug response in cancer, there are none for metastatic renal cell carcinoma, or for its standard therapy; anti-angiogenic agents, which have doubled the median overall survival of patients since their introduction a decade ago.

However, not all patients show a positive response. "There is a percentage who are refractory to this therapy," explains Cristina Rodríguez-Antona, from the Hereditary Endocrine Cancer Group at the CNIO. "This implies that the tumour will continue to grow in the presence of TKIs".

At present, there is no way of knowing how each patient will respond but "if we could identify them in advance, we could apply the most appropriate treatment," stressed the researcher.

Immersed in the search for biomarkers, this team considered that the miRNAs would be good candidates.

These small molecules act as regulators in several biological processes -programmed cell death, proliferation and differentiation, for example- and they are also very stable, which facilitates their preservation in tissue samples.

As a first approach, the authors performed a deep sequencing of the miRNAs in samples from 74 patients treated with TKIs.

Of these, 16 (22%) already showed disease progression in the first control, while in 58 (78%) the tumour presented full or partial responses to treatment or disease stabilisation.

After several analyses and adjustments, of the 65 miRNAs whose expression was significantly different in the fast-growing tumours compared to the stable ones, six appeared to be "easily detectable biomarkers" and were selected for an independent validation.

Five of them were still associated with a poor response to the TKIs and appeared to be independent of patient prognosis.

"The next-generation sequencing has allowed us to detect all the miRNAs in quite a large cohort [of patients]," says Rodríguez-Antona. "To date, other studies used small series and weaker techniques and, therefore, the results were limited."

In order to strengthen this first finding, the authors generated a predictive model in a group of 132 patients.

First, they considered the five differentially expressed miRNAs, in addition to other clinical characteristics (prognostic group, age, sex...) and, after several analyses, they identified a model based on two miRNAs that showed "higher accuracy than any clinical factor tested", regarding the prediction of how the tumour would respond to TKI-based treatments.

With the arrival of novel drugs and the different responses displayed by patients, "we are going to need biomarkers to guide treatment selection," says Rodríguez-Antona.

This paper shows that miRNAs are good predictive markers of the response to TKIs.

Although researchers point out that "these results will have to be validated in other patient series before using them to personalise treatments for metastatic renal cancer".

Source: JCI Insight